Nasal Drugs Show Promise for Slowing Parkinson's Disease Progression

Two new intranasal drugs slow inflammation and stop the spread of alpha-synuclein in mouse models of Parkinson's disease. The drug also improved gait and balance in the animals. If the results are able to be replicated in humans, researchers say the drugs could be hailed as a "remarkable advance" in the treatment of Parkinson's disease.